Loading clinical trials...
Loading clinical trials...
A Randomized and Open-label Dose-finding, Ph. 2, Efficacy, Safety, and Pharmacokinetic Study of Once-per-cycle Prophylactic Injections of ANF-RHO™ Versus Pegfilgrastim (Neulasta®) in Non-metastatic Breast Cancer Patients at High-risk of Chemotherapy-induced Neutropenia
Conditions
Interventions
ANF-RHO™
Neulasta®
Locations
8
France
Hôpital Saint Louis - Center des Maladies du Sein
Paris, France
Institut de cancérologie Jean Godinot
Reims, France
Strasbourg Oncologie Libérale
Strasbourg, France
CHU de Tours
Tours, France
Erasmus Medical Center
Rotterdam, Netherlands
Ikazia Ziekenhuis
Rotterdam, Netherlands
Start Date
August 3, 2017
Primary Completion Date
April 18, 2018
Completion Date
May 22, 2018
Last Updated
February 12, 2019
NCT06537726
NCT05245487
NCT04345900
NCT04101760
NCT03251768
NCT02454530
Lead Sponsor
Prolong Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions